Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MRNA

Moderna, Inc.

Healthcare | Biotechnology
$45.17 -5.56 (-10.96%) as of 2026-07-14 20:11 UTC
Market Cap$17.8B
EPS (TTM)$-7.26

Moderna, Inc. (NASDAQ: MRNA) is a $17.8B biotechnology company trading at $45.17 (−11.0% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 20:11 UTC.

52-Week Range
Low $44.62High $56.20

What Moderna, Inc. does

Moderna is a company that develops medicines using mRNA technology, which enables cells to produce specific proteins for treating and preventing diseases. The company currently sells three commercial products: Spikevax and mNEXSPIKE (COVID vaccines) and mRESVIA (an RSV vaccine), generating total revenue largely from COVID vaccine sales. Beyond these products, Moderna is advancing a pipeline of candidates in oncology, rare disease, and infectious disease, including a personalized cancer therapy developed with Merck, seasonal flu vaccine candidates, and treatments for rare metabolic disorders.

Summarized from Moderna, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$45.17
Change (1D)-5.56 (-10.96%)
Market cap$17.8B
52-week range$44.62 – $56.20
Valuation
EPS (TTM)$-7.26
Price/book2.06×
Debt/equity0.07
Returns
52-week return+1.2%
Revenue, margins & earnings
FY2021 Net income: $12.2BFY2021 Taxes & interest: $1.09BFY2021 Operating costs: $5.17B$18.5BFY2021FY2022 Net income: $8.36BFY2022 Taxes & interest: $1.06BFY2022 Operating costs: $9.84B$19.3BFY2022FY2023: net loss $4.71B on revenue $6.85B$6.85BFY2023FY2024: net loss $3.56B on revenue $3.24B$3.24BFY2024FY2025: net loss $2.82B on revenue $1.94B$1.94BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-10
  • 2026-07-10McDonnell Michael R.A7,415—
  • 2026-07-10McDonnell Michael R.A1,618—
  • 2026-07-10McDonnell Michael R.A5,733—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • FMR LLC45,559,407$2.31B+62.5%
  • VANGUARD GROUP INC40,463,628$1.19B-1.8%
  • BlackRock, Inc.22,995,385$1.17B-29.3%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Moderna, Inc. do?

Moderna is a company that develops medicines using mRNA technology, which enables cells to produce specific proteins for treating and preventing diseases.

What is MRNA's valuation?

MRNA trades at $45.17, as of 2026-07-14.

When did MRNA last file with the SEC?

Moderna, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 20:11 UTC. This page is also available as JSON at /api/data?ticker=MRNA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MRNA and 3,500+ tickers.

Create a free account — keep MRNA
For your agent
GET /api/data?ticker=MRNA

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt